We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Industry Suggests New Meeting for Biosimilars Development Process
Industry Suggests New Meeting for Biosimilars Development Process
September 2, 2011
The FDA and biosimilar interest groups are working to revamp the proposed biosimilars product development process, with industry asking for an additional development meeting type with fewer data review components and a shorter performance goal timeframe.